GlassScriptPhysician profile
Kara M Cain
NPI 1548726482
$14,583.84
in general payments reported to CMS, 2019-2025
34 companies · $4,915 in 2025
The $4,915 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,840 · 2022: $2,532 · 2023: $524 · 2024: $3,773 · 2025: $4,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,211.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,690.10 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,336.04 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,242.03 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $902.07 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $761.33 | 2023-2025 | Voquezna |
| Gilead Sciences, INC. | $654.41 | 2021-2025 | |
| Ardelyx, INC. | $478.90 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $448.78 | 2023-2025 | |
| Qol Medical, LLC | $444.66 | 2021-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $378.35 | 2021-2024 | Linzess |
| Pfizer INC. | $377.87 | 2022-2025 | |
| Lilly USA, LLC | $368.74 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $343.43 | 2021-2025 | Injectafer |
| Nestle Healthcare Nutrition INC. | $312.87 | 2021-2022 | |
| Celgene Corporation | $213.67 | 2021-2024 | Zeposia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $203.77 | 2021-2025 | Ocaliva |
| Medtronic, INC. | $193.85 | 2021-2024 | Interstim |
| Madrigal Pharmaceuticals | $176.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $119.56 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $117.64 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $114.81 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.44 | 2023 | Lifevest |
| Ipsen Biopharmaceuticals, INC | $100.74 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $80.53 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $71.17 | 2021-2024 | Dificid |
| Alnylam Pharmaceuticals INC. | $70.38 | 2024-2025 | Givlaari |
| Mallinckrodt Hospital Products INC. | $63.19 | 2024-2025 | Terlivaz |
| Novo Nordisk INC | $61.79 | 2025 | Wegovy |
| Intra-Sana Laboratories | $35.15 | 2021-2022 | |
| Revance Therapeutics, INC. | $33.41 | 2025 | Daxxify |
| Janssen Scientific Affairs, LLC | $25.30 | 2024 | Tremfya |
| Enterra Medical, INC. | $24.05 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.18 | 2022 | |
| Axonics, INC. | $16.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.